The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Tempus AI stock surged 40% YTD, driven by acquisitions and investor confidence in healthcare AI. Can its momentum spark broader industry growth?

Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the appointment of Aaron ...

The deal also brings integration and execution risks. Ambry, a 25-year-old genetics testing firm, is expected to generate over $300 million in revenue this year, with growth boosted by market ...

Researchers from Mass General Brigham, Harvard Medical School and Duke University School of Medicine have identified nearly 300 genetic disorders that can be treated before or immediately after a baby ...

Marcy Richardson from Ambry Genetics discusses the importance of a new study that assessed the functional impact of thousands of BRCA2 variants, identifying those that may increase cancer risk. What ...

Researchers from Mass General Brigham , Harvard Medical School and Duke University School of Medicine have identified nearly ...

Aaron joins Freenome most recently from REALM IDx, Inc., where he served as CEO and president for nearly four years, overseeing its subsidiaries Ambry Genetics, Invicro and Konica Minolta REALM-Japan.